Temasek’s Advanced MedTech appoints new CEO

The leadership change follows a banner year for the company

Ry-Anne Lim
Published Tue, Jul 2, 2024 · 09:00 AM
    • Wong Yau Chung will be Advanced MedTech's group chief executive officer from Oct 1.
    • Advanced MedTech's FY2024 group revenue is up 15.1 per cent year on year to US$335 million.
    • Wong Yau Chung will be Advanced MedTech's group chief executive officer from Oct 1. PHOTO: ADVANCED MEDTECH
    • Advanced MedTech's FY2024 group revenue is up 15.1 per cent year on year to US$335 million. PHOTO: BT FILE

    ADVANCED MedTech, a medical device company that is a wholly owned subsidiary of Singapore’s state-owned investment firm Temasek, has appointed Wong Yau Chung as its new group chief executive officer, effective Oct 1. 

    He was previously the group chief operating officer and on Monday (Jul 1) assumed the role of group CEO-designate. 

    Wong succeeds Abel Ang, who has been CEO since 2014. Ang will retire as group CEO as part of a planned leadership transition, but will remain on the board of directors, said Advanced MedTech. 

    The change in leadership follows a banner year for the group. 

    In the financial year ended Mar 31, 2024, the group earned US$335 million in revenue, up 15.1 per cent from a year ago. Excluding Covid-19-related revenues, this was a 17.4 per cent increase.

    Revenue rose at a compound annual growth rate of 9.5 per cent between FY2022 and FY2024, and 16.4 per cent in the same period excluding Covid-19-related revenues.

    BT in your inbox

    Start and end each day with the latest news stories and analyses delivered straight to your inbox.

    “These record results...is testament to the effective execution of (the group’s) vision, driven by strong leadership and a clear strategic focus,” said the company’s chairman, Philip Yeo. (*see amendment note)

    “It is a testament to the effective execution of (the group’s) vision, driven by strong leadership and a clear strategic focus.”

    Wong added: “I am honoured and excited to lead Advanced MedTech into a new chapter and its next phase of growth and innovation.” 

    “With the support of our incredibly talented team, I look forward to building upon our record success in FY2024 and continuing to drive growth in a sustainable manner,” he said. 

    (*Amendment note: A previous version of the article quoted Advanced MedTech as being among the top three for investment returns within the Temasek portfolio over the last three years. The group has retracted the statement.) 

    Copyright SPH Media. All rights reserved.